studies on semaglutide Research Study - SemaglutideSTEP 5 approximately 70% of participants achieved a weight loss of at least 10 Comprehensive Studies on Semaglutide: Efficacy, Safety, and Long-Term Impact

Semaglutidelong-termstudies Semaglutide (SMG), a GLP-1 receptor agonist, has emerged as a significant therapeutic agent, particularly in the realm of weight management and metabolic health作者：R Salvador·2025·被引用次数：17—This review addresses the role ofsemaglutide (SMG), a GLP-1 receptor agonist, in the treatment of obesity and its related comorbidities.. Extensive studies on semaglutide have been conducted to evaluate its efficacy, safety, and long-term impact, providing valuable insights into its role in treating conditions such as obesity and type 2 diabetes. This article synthesizes findings from key clinical studies to offer a comprehensive overview of this innovative medicationThe Role of Semaglutide in Weight Management.

Efficacy in Weight Management

Numerous studies highlight the substantial weight loss potential of semaglutide作者：S Wharton·2025·被引用次数：24—Conclusions. Oralsemaglutideat a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants .... The STEP trials, a series of pivotal clinical studies, have consistently demonstrated impressive results1天前—Ozempic and other weight-loss drugs linked to sudden vision loss,two studies suggest... Semaglutide was not designed as a lifestyle product.. For instance, in the STEP 1 study, once-weekly subcutaneous semaglutide at a 2.4 mg dose achieved a mean weight loss of 14.9%–171天前—Ozempic and other weight-loss drugs linked to sudden vision loss,two studies suggest... Semaglutide was not designed as a lifestyle product..4% at 68 weeks in participants without diabetes. Another significant finding from the STEP 5 trial indicates that semaglutide 7.2 mg was superior to placebo and 2.作者：AM Chao·2023·被引用次数：269—Semaglutide has demonstrated the largest weight loss of any obesity medicationto date with reductions of approximately 15% of initial weight at 68 weeks.4 mg for bodyweight reduction in adults with obesity, with an average reduction in weight of 20.10小时前—The FDA approved oralsemaglutideto reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).7%. These results underscore that semaglutide has demonstrated the largest weight loss of any obesity medication to date2天前—Adults with obesity or type 2 diabetes receivingsemaglutideor tirzepatide frequently did not receive adequate nutritional guidance..

Furthermore, real-world data supports these clinical trial findings. A systematic review and meta-analysis of randomized controlled trials suggest that semaglutide is beneficial for promoting sustained weight loss in adults with overweight/obesity and without diabetes.STEP UP Trial Shows Semaglutide 7.2 mg Achieves ... The semaglutide long-term studies also indicate significant outcomes, with analyses showing that 61.Semaglutide pill works for significant weight loss, study finds8% of participants on semaglutide lost ≥10% of baseline weight, and over a third achieved at least a 20% weight loss作者：WT Garvey·2022·被引用次数：832—Moreover,61.8% of participants on semaglutide lost ≥10% of baseline weight, and over a third of participants had achieved at least 20% weight .... Even after treatment cessation, one study did show successful weight loss maintenance over four years with continuous semaglutide treatmentWeight regain after cessation of medication for .... However, it's also important to note that following treatment withdrawal, there can be a tendency for weight regain; one meta-analysis of 37 studies including 9,341 adults indicated that weight increased by an average of 0Elon Musk's Semaglutide Experience: How He's Tackling Weight Loss ....4 kg (0.Once-Weekly Semaglutide in Adults with Overweight or ...9 pounds) per month after weight management drugs were stopped. Adherence to the treatment regimen is also crucial, as indicated by research showing that patients who received fewer than 12 orders achieved a significantly lower weight loss percentage than those who received 12 or more orders.

Different Formulations and Dosing

The development of semaglutide has expanded to include different administration routes. While the injectable form has been extensively studied, research is also progressing on oral semaglutide. A study on oral semaglutide at a dose of 25 mg once daily reported a clinically relevant mean reduction in body weight of 13.6 percent (11.4 kg) in participants. This development offers a more convenient option for some individuals seeking weight loss. The STEP UP Trial also explored higher doses, showing semaglutide 7作者：A Moiz·2024·被引用次数：77—Our results suggest thatsemaglutide is beneficial for promoting sustained weight lossin adults with overweight/obesity and without diabetes..2 mg significantly outperformed semaglutide 2.Nutritional Guidance Lacking for Adults Receiving ...4 mg and placebo in terms of bodyweight reductionSemaglutide Long-Term Side Effects - Healthline.

Safety and Tolerability

The safety profile of semaglutide has been a critical aspect of its evaluation through various studies.Concerns with Semaglutide and Other GLP-1 Receptor Agonists Real-world safety data for once-weekly semaglutide in adults with type 2 diabetes has identified no new safety concerns, indicating that it is well-tolerated. However, as with any medication, potential side effects exist. Concerns have been raised regarding semaglutide and other GLP-1 receptor agonists, and two studies suggest a potential link to vision disturbances.Real-world safety profile of once-weekly semaglutide in ... It is important for individuals to discuss any potential concerns with semaglutide and other GLP-1 receptor agonists with their healthcare provider作者：M Krajnc·2025·被引用次数：2—After one year of treatmentbody weight was significantly lower by 5.7% (5.9 kg) in completers, and BMI decreased significantly by an average of .... Rare, but serious, risks such as thyroid C-cell tumors have been observed in rodent studies, though the relevance to humans is still under investigation.

Emerging Research and Future Directions

Beyond weight management, studies are exploring the broader therapeutic applications of semaglutide. Research is underway to evaluate if semaglutide can slow down the progression of chronic kidney disease in individuals with type 2 diabetes. Additionally, semaglutide is being investigated to see if it may reduce the risk of having cardiovascular events in patients who are overweight or obese. The FDA has also approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes.

Recent findings also highlight the need for comprehensive patient supportSemaglutide pill works for significant weight loss, study finds. Adults with obesity or type 2 diabetes receiving semaglutide or tirzepatide frequently did not receive adequate nutritional guidance, suggesting an area for improvement in patient care protocols.

In conclusion, a robust body of studies on semaglutide has established its efficacy as a powerful tool for weight loss and managing metabolic conditions. While ongoing research continues to expand our understanding of its benefits and potential risks, semaglutide represents a significant advancement in pharmacological interventions for obesity and related comorbidities. The semaglutide STEP trials, in particular, have been instrumental in demonstrating its profound impact on weight loss, with ongoing investigations aiming to further solidify its role in cardiovascular health and kidney disease management.